




ISOPURE SERENITY
ENHANCED MONOFOCAL IOL



ISOPURE SERENITY
ENHANCED MONOFOCAL IOL

Expand Everyday Vision

The standard of care for your monofocal patients




ISOPURE SERENITY Enhanced Monofocal IOL

Expanding the range of vision while maintaining the uncompromised visual quality of a monofocal platform.


Uncompromised quality and extended range of vision

ISOPURE SERENITY provides excellent distance vision while extending functional intermediate vision, maintaining the visual quality, contrast sensitivity and photic phenomena profile expected from a monofocal IOL.¹⁻²

- **98%** of patients achieved **20/20 distance vision**.¹
- **77%** of patients achieved **20/32 intermediate vision** at 80 cm and 66 cm.¹
- **Excellent contrast sensitivity and photic phenomena** comparable to a standard aspheric monofocal IOL.²
- Clinical evidence across **different patient populations**.³



Mean photopic binocular defocus curve. Data from published ISOPURE SERENITY studies are shown for comparison.¹




Mean binocular mesopic contrast sensitivity comparing ISOPURE 1.2.3 and Micropure 1.2.3 IOLs at 4–6 months post-surgery.^{2,3}

Power-optimized for consistent optical performance

ISOPURE SERENITY features proprietary ISOFOCAL™ technology, based on a continuous aspheric optical design that maintains consistent optical performance across the full dioptric range.

Unlike conventional aspheric IOLs, the optical profile is specifically engineered for each lens power to provide visual performance and monofocal-like visual quality.⁴⁻⁶



- Aspherical anterior and posterior surfaces working together to increase depth of focus
- Continuous, power-optimized spherical aberration across the full optical surface

Lens Power Profiles to adjust negative SA



Please note that these drawings are for illustrative purposes only and serve as a general representation of the Intraocular Lens (IOL) design.


Excellent stability, maneuverability and accuracy

Built on the clinically proven POD Platform, ISOPURE SERENITY combines optimal rotational stability, maneuverability and high refractive accuracy featuring BVI's unique open double C-loop haptic design.

The same trusted platform also supports the ISOPURE SERENITY family, including ISOPURE SERENITY Toric, extending these benefits to accurate astigmatism correction.⁷⁻¹³

- 1.22° average rotation⁷
- 98% of eyes rotated $<10^{\circ}$

1.22°
average rotation for
the PODEYE Toric lens.



N = 94 eyes

Monofocal-like surgical workflow

ISOPURE SERENITY fits naturally into routine cataract surgery while expanding what you can offer your monofocal patients.

Its non-diffractive optical design supports straightforward patient counselling, while handling, implantation and surgical technique remain as familiar as with a conventional monofocal IOL.

Technical Specifications

Model	ISOPURE TORIC							
Material	GFY Hydrophobic Acrylic							
Overall diameter	11.40mm							
Optic diameter	6.00mm							
Optic	Polynomial Surface Design							
Haptic design	Double C-Loop with Ridgetech & Posterior Angulated Haptic							
Filtration	UV & Blue Light							
Refractive index	1.53							
Abbe number	42							
Injection system	Medicel Accuject Injector 2.0 / 2.1 / 2.2*							
Spherical power ²³	+10D to +30D (0.5D steps) +31D to +35D (1D steps)							
Suggested A constant ²²				Interferometry				
	Hoffer Q: pACD			5.85				
	Holladay 1: Sf			2.06				
	Barrett: LF			2.09				
	SRK/T: A			119.40				
	Haigis: a0; a1; a2			1.70; 0.4; 0.1				
	SERENITY TORIC 1.0	SERENITY TORIC 1.5	SERENITY TORIC 2.25	SERENITY TORIC 3.0	SERENITY TORIC 3.75	SERENITY TORIC 4.5	SERENITY TORIC 5.25	SERENITY TORIC 6.0
Cylinder power at IOL plane	1.00D	1.50D	2.25D	3.00D	3.75D	4.50D	5.25D	6.00D
Cylinder power at corneal plane	0.68D	1.03D	1.55D	2.06D	2.57D	3.08D	3.60D	4.11D



*The Medicel Accuject Injector 2.0 should be used for lenses up to +24.5D and Medicel Accuject 2.1 / 2.2 is to be used for the full range.

Expand Everyday Vision

The standard of care for your monofocal patients

The ISOPURE SERENITY family is designed to expand everyday vision while preserving the visual quality and familiar workflow expected from a monofocal IOL. With ISOPURE SERENITY and ISOPURE SERENITY Toric, you can address a broader range of patients' needs on the same trusted platform.

Uncompromised quality and extended range of vision

Power-optimized for consistent optical performance

Excellent stability, maneuverability and accuracy

Monofocal-like surgical workflow



References:

1. Daya S, Akahoshi T, Bosc C, et al. Clinical outcomes of a multicenter study following implantation of an isofocal optic IOL with double C-loop haptics. *Clin Ophthalmol.* 2025;19:3121–3131. **2.** Ang RET, Stodulka P, Poyales F. Prospective randomized single-masked study of bilateral isofocal optic-design or monofocal intraocular lenses. *Clin Ophthalmol.* 2023;17:2231–2242. **3.** Akahoshi T. Evaluation of Clinical Outcomes of an Isofocal Optic-Design Intraocular Lens with double C-Loop Haptics in Eyes with Glaucoma. *J Clin Med.* 2026, 15, 5730 **4.** BVI internal data. **5.** Lago CM, de Castro A, Benedí-García C, Aissati S, Marcos S. Evaluating the effect of ocular aberrations on the simulated performance of a new refractive IOL design using adaptive optics. *Biomed Opt Express.* 2022;13(12):6682. **6.** Pérez-Sanz L, González Fernández V, Gómez-Pedrero JA, et al. Optical and clinical outcomes of an isofocal intraocular lens vs. a monofocal standard lens. *Life.* 2023;13:2001. **7.** Ang RET, Tañá-Rivero P, Pastor-Pascual F, et al. Visual and refractive outcomes after bilateral implantation of a biconvex aspheric toric monofocal intraocular with a double C-loop haptic design. *Clin Ophthalmol.* 2023;17:2765–2776. **8.** Ang RET. Long-term trifocal toric intraocular lens outcomes in Asian eyes after cataract surgery. *J Cataract Refract Surg.* 2023;49(8):832–839. **9.** Daya S, Espinosa Lagana M. Visual and refractive outcomes of a new hydrophobic trifocal toric intraocular lens. *Clin Ophthalmol.* 2024;18:997–1007. **10.** Akahoshi T. Hydrophobic trifocal toric intraocular lens outcomes in Japanese eyes after cataract surgery. *Clin Ophthalmol.* 2024;18:2021–2031. **11.** Ang RET. PODEYE toric clinical outcomes. Presentation, BVI Advisory Board meeting, Boston, 2024. **12.** Torio et al. Comparison of the Rotational Stability of Different Toric Intraocular Lens Implants. *Philipp J Ophthalmol.* 2014;39:67-72. **13.** Abulafia A, Koch DD. New regression formula for toric intraocular lens calculations. *J Cataract Refract Surg.* 2016;42:663–671.



Contact Information:

www.bvimedical.com/customer-support/

CE MDR 735726 R000

BVI and all other trademarks (unless noted otherwise) are property of BVI. BVI ©2024



1915344-01